[Executive Summary](index=1&type=section&id=Executive%20Summary) [Q2 2025 Key Financial Highlights](index=1&type=section&id=Q2%202025%20Key%20Financial%20Highlights) AMN Healthcare's Q2 2025 revenue was **$658.2 million** (down **11%**), adjusted EBITDA **$58.3 million** (down **38%**), and GAAP net loss **$116.2 million** from impairment | Metric | Q2 2025 (Millions USD) | YoY Change (%) | H1 2025 (Millions USD) | YoY Change (%) | | :--- | :--- | :--- | :--- | :--- | | Revenue | $658.2 | (11%) | $1,347.7 | (14%) | | Gross Profit | $196.4 | (15%) | $394.5 | (19%) | | Net Loss | ($116.2) | nm | ($117.3) | nm | | Diluted EPS Loss | ($3.02) | nm | ($3.06) | nm | | Adjusted Diluted EPS* | $0.30 | (69%) | $0.75 | (62%) | | Adjusted EBITDA* | $58.3 | (38%) | $122.5 | (36%) | - GAAP loss includes **$128 million** in non-cash goodwill and intangible asset impairment charges, equivalent to **$2.81** per share[3](index=3&type=chunk) [Business Highlights](index=1&type=section&id=Business%20Highlights) Q2 highlights include revenue and adjusted EBITDA margin exceeding guidance, strong operating cash flow, and a strategic divestiture - Q2 revenue was near the high end of guidance, and adjusted EBITDA margin exceeded guidance[3](index=3&type=chunk) - Allied staffing revenue exceeded expectations[3](index=3&type=chunk) - AMN Passport users surpassed **300,000**[3](index=3&type=chunk) - Smart Square was sold in July for **$75 million**, advancing the WorkWise technology platform partnership strategy[3](index=3&type=chunk) - Operating cash flow reached **$79 million**, reducing debt by **$80 million**, with a net leverage ratio of **3.3:1**[3](index=3&type=chunk) [CEO Commentary](index=2&type=section&id=CEO%20Commentary) CEO noted solid Q2 performance, market progress, stable July orders, and rebounding renewal rates despite policy uncertainties - The company demonstrated solid Q2 financial performance and continued progress in serving all market channels and being a preferred workforce partner[4](index=4&type=chunk) - Third-party rankings confirmed AMN maintained market share in a competitive environment[4](index=4&type=chunk) - Enhanced AI and technology services, broad solutions, and talent teams are expected to drive future market share gains[4](index=4&type=chunk) - Uncertain healthcare policy slowed client decision-making in Q2, but July orders stabilized, and renewal rates rebounded[4](index=4&type=chunk) [Second Quarter 2025 Financial Results](index=2&type=section&id=Second%20Quarter%202025%20Financial%20Results) [Consolidated Results](index=2&type=section&id=Consolidated%20Results) AMN Healthcare's Q2 2025 consolidated revenue was **$658 million** (down **11%**), resulting in a **$116 million** net loss and **$0.30** adjusted diluted EPS | Metric | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Consolidated Revenue | $658 Million | $740 Million | -11% | | Net Loss | ($116) Million | $16 Million | nm | | Diluted EPS Loss | ($3.02) | $0.42 | nm | | Adjusted Diluted EPS | $0.30 | $0.98 | -69% | [Segment Performance](index=2&type=section&id=Segment%20Performance) All segments experienced revenue declines, with Nurse and Allied Solutions down **14%**, Physician and Leadership Solutions down **6%**, and Technology and Workforce Solutions down **9%** [Nurse and Allied Solutions](index=2&type=section&id=Nurse%20and%20Allied%20Solutions) Nurse and Allied Solutions revenue decreased to **$382 million** (down **14%**), driven by travel nurse and allied staffing declines, with **$16 million** from labor disruption | Metric | Q2 2025 (Millions USD) | YoY Change (%) | QoQ Change (%) | | :--- | :--- | :--- | :--- | | Nurse and Allied Solutions Revenue | $382 | (14%) | (8%) | | Travel Nurse Staffing Revenue | - | (25%) | (4%) | | Allied Staffing Revenue | - | (4%) | (1%) | | Labor Disruption Revenue Contribution | $16 | - | - | [Physician and Leadership Solutions](index=2&type=section&id=Physician%20and%20Leadership%20Solutions) Physician and Leadership Solutions revenue was **$175 million** (down **6%**), with flat locum tenens revenue but declines in interim leadership and search | Metric | Q2 2025 (Millions USD) | YoY Change (%) | QoQ Change (%) | | :--- | :--- | :--- | :--- | | Physician and Leadership Solutions Revenue | $175 | (6%) | 0% | | Locum Tenens Revenue | $143 | 0% | 1% | | Interim Leadership Revenue | - | (25%) | (5%) | | Physician and Leadership Search Revenue | - | (29%) | (2%) | [Technology and Workforce Solutions](index=3&type=section&id=Technology%20and%20Workforce%20Solutions) Technology and Workforce Solutions revenue was **$102 million** (down **9%**), with language services growing **1%** while VMS revenue declined **31%** | Metric | Q2 2025 (Millions USD) | YoY Change (%) | QoQ Change (%) | | :--- | :--- | :--- | :--- | | Technology and Workforce Solutions Revenue | $102 | (9%) | 0% | | Language Services Revenue | $76 | 1% | 1% | | VMS Revenue | $19 | (31%) | (2%) | [Key Financial Metrics](index=3&type=section&id=Key%20Financial%20Metrics) Consolidated gross margin was **29.8%** (down **120 bps**), with an operating loss of **$124 million** due to impairment, and adjusted EBITDA of **$58 million** (down **38%**) | Metric | Q2 2025 | Q2 2024 | YoY Change | | :--- | :--- | :--- | :--- | | Consolidated Gross Margin | 29.8% | 31.0% | -120 bps | | SG&A Expenses (% of Revenue) | 23.5% | 20.1% | +340 bps | | Operating Loss | ($124) Million | $38 Million | nm | | Operating Margin | (18.8%) | 5.1% | -2390 bps | | Adjusted EBITDA | $58 Million | $94 Million | -38% | | Adjusted EBITDA Margin | 8.9% | 12.7% | -380 bps | - The year-over-year increase in SG&A expenses was primarily due to unfavorable actuarial adjustments for professional liability insurance this year[10](index=10&type=chunk) - Operating loss primarily resulted from **$128 million** in non-cash goodwill and intangible asset impairment charges[11](index=11&type=chunk) [Balance Sheet and Cash Flow Highlights](index=3&type=section&id=Balance%20Sheet%20and%20Cash%20Flow%20Highlights) As of June 30, 2025, the company held **$42 million** in cash, generated **$79 million** in Q2 operating cash flow, and had **$920 million** in total debt | Metric | As of June 30, 2025 (Millions USD) | | :--- | :--- | | Cash and Cash Equivalents | $42 | | Operating Cash Flow (Q2) | $79 | | Capital Expenditures (Q2) | $10 | | Total Debt | $920 | [Strategic Transactions](index=3&type=section&id=Strategic%20Transactions) AMN Healthcare sold Smart Square for **$75 million** in July, projecting annual revenue and adjusted EBITDA reductions of **$17 million** and **$6 million** - Smart Square nurse scheduling software was sold to symplr in July for **$65 million** in cash and a **$10 million** 18-month note[13](index=13&type=chunk) - The divestiture is expected to reduce Technology and Workforce Solutions and consolidated revenue by approximately **$17 million** annually, and adjusted EBITDA by approximately **$6 million** annually[14](index=14&type=chunk) [Third Quarter 2025 Outlook](index=5&type=section&id=Third%20Quarter%202025%20Outlook) [Consolidated Guidance](index=5&type=section&id=Consolidated%20Guidance) Q3 2025 consolidated revenue is projected between **$610-625 million**, with gross margin **28.7-29.2%** and adjusted EBITDA margin **7.7-8.2%** | Metric | Guidance Range | | :--- | :--- | | Consolidated Revenue | $610 - $625 Million | | Gross Margin | 28.7% - 29.2% | | SG&A as % of Revenue | Approx 23.0% | | Operating Margin | 6.0% - 6.5% | | Adjusted EBITDA Margin | 7.7% - 8.2% | - Q3 2025 revenue is projected to decrease by **9-11%** year-over-year and **5-7%** sequentially[16](index=16&type=chunk) [Segment Revenue Projections](index=5&type=section&id=Segment%20Revenue%20Projections) Q3 segment revenues are expected to decline: Nurse and Allied Solutions down **11-14%**, Physician and Leadership Solutions down **2-4%**, and Technology and Workforce Solutions down **12-14%** | Business Segment | Q3 2025 Revenue YoY Change | | :--- | :--- | | Nurse and Allied Solutions | Down 11-14% | | Physician and Leadership Solutions | Down 2-4% | | Technology and Workforce Solutions | Down 12-14% | - Guidance assumes **$5 million** in labor disruption revenue[16](index=16&type=chunk) [Other Financial Estimates](index=5&type=section&id=Other%20Financial%20Estimates) Q3 financial estimates include **$17 million** depreciation, **$21 million** non-cash amortization, **$7.5 million** stock-based compensation, and **$10.5 million** interest expense | Item | Q3 2025 Estimate (Millions USD) | | :--- | :--- | | Depreciation | $17 | | Depreciation in Cost of Revenue | $2 | | Non-Cash Amortization Expense | $21 | | Stock-Based Compensation Expense | $7.5 | | Integration and Other Costs | $2.5 | | Interest Expense | $10.5 | | Adjusted Tax Rate | 28% | | Average Diluted Shares Outstanding | 38.7 Million Shares | | Smart Square Divestiture Gain (Assumed) | $40 | [Company Information](index=6&type=section&id=Company%20Information) [About AMN Healthcare](index=6&type=section&id=About%20AMN%20Healthcare) AMN Healthcare is a leading US healthcare talent solutions innovator, serving over **2,100** systems and **15 million** patients in 2024 with comprehensive staffing and technology - AMN Healthcare is a leader and innovator in healthcare talent solutions in the United States[20](index=20&type=chunk) - In **2024**, the company served over **2,100** healthcare systems, including **87%** of the nation's top systems, and nearly **15 million** patients[20](index=20&type=chunk) - The company provides a comprehensive network of healthcare professionals and an integrated suite of customized workforce technologies[20](index=20&type=chunk) - The company's common stock is listed on the New York Stock Exchange under the ticker symbol “AMN”[21](index=21&type=chunk) [Conference Call Details](index=6&type=section&id=Conference%20Call%20Details) AMN Healthcare will host a conference call on August 7, 2025, at 5:00 PM ET to discuss Q2 2025 results and Q3 outlook - The conference call will be held on August **7**, **2025**, at **5:00 PM ET**[19](index=19&type=chunk) - Discussion will cover Q2 **2025** financial results and the Q3 outlook[19](index=19&type=chunk) [Non-GAAP Measures](index=6&type=section&id=Non-GAAP%20Measures) [Explanation and Reconciliation](index=6&type=section&id=Explanation%20and%20Reconciliation) This report includes non-GAAP financial measures like adjusted EBITDA and diluted EPS, provided as supplemental information to assess operational performance - Non-GAAP financial measures include Adjusted EBITDA, Adjusted EBITDA Margin, Adjusted Net Income, and Adjusted Diluted EPS[22](index=22&type=chunk) - Management believes these metrics aid in evaluating the company's operating performance and serve as industry-wide financial measures[23](index=23&type=chunk) - Non-GAAP metrics should not be used in isolation, and their reconciliation tables and detailed explanations are available in the “Non-GAAP Reconciliation Tables”[23](index=23&type=chunk) [Forward-Looking Statements & Risk Factors](index=7&type=section&id=Forward-Looking%20Statements%20%26%20Risk%20Factors) [Forward-Looking Statements Disclaimer](index=7&type=section&id=Forward-Looking%20Statements%20Disclaimer) This press release contains forward-looking statements regarding future demand, market share, AI investments, and Q3 2025 projections, with actual results potentially differing materially - This press release contains “forward-looking statements” concerning future demand, market share, AI and technology investments, revenue diversification, healthcare policy impacts, and Q3 **2025** financial projections[24](index=24&type=chunk) - Actual results may differ materially from forward-looking statements[24](index=24&type=chunk) - The company undertakes no obligation to update or revise any forward-looking statements[28](index=28&type=chunk) [Key Risk Factors](index=8&type=section&id=Key%20Risk%20Factors) Forward-looking statements depend on factors like client staffing efficiency, hospital temporary staff utilization, post-pandemic impacts, and talent retention - Risk factors include clients' ability to improve staffing efficiency, hospitals' adjustment to temporary staff utilization, post-pandemic effects, and the ability to attract and retain healthcare professionals[26](index=26&type=chunk) - Ability to adapt to market changes, impact of economic downturns and inflation, technology product development, regulatory compliance, M&A integration, and negative impacts from intermediaries[26](index=26&type=chunk) - Labor market disruptions, cybersecurity incidents, and hospitals' ability to pay[26](index=26&type=chunk)[27](index=27&type=chunk) [Financial Statements](index=10&type=section&id=Financial%20Statements) [Condensed Consolidated Statements of Comprehensive Income (Loss)](index=10&type=section&id=Condensed%20Consolidated%20Statements%20of%20Comprehensive%20Income%20(Loss)) This section presents AMN Healthcare Services, Inc.'s unaudited condensed consolidated statements of comprehensive income (loss) for Q2 and H1 2025 and 2024 | Metric (Thousands USD) | Q2 2025 | Q2 2024 | Q1 2025 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | :--- | | Revenue | $658,175 | $740,685 | $689,533 | $1,347,708 | $1,561,563 | | Cost of Revenue | $461,776 | $510,858 | $491,413 | $953,189 | $1,074,230 | | Gross Profit | $196,399 | $229,827 | $198,120 | $394,519 | $487,333 | | Operating Loss | ($123,715) | $37,682 | $12,507 | ($111,208) | $77,627 | | Net Income (Loss) | ($116,202) | $16,237 | ($1,092) | ($117,294) | $33,565 | | Diluted EPS Loss | ($3.02) | $0.42 | ($0.03) | ($3.06) | $0.88 | [Condensed Consolidated Balance Sheets](index=12&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) This section presents AMN Healthcare Services, Inc.'s unaudited condensed consolidated balance sheets as of June 30, 2025, December 31, 2024, and June 30, 2024 | Metric (Thousands USD) | June 30, 2025 | December 31, 2024 | June 30, 2024 | | :--- | :--- | :--- | :--- | | Cash and Cash Equivalents | $41,503 | $10,649 | $48,038 | | Total Current Assets | $571,351 | $594,915 | $704,757 | | Goodwill | $755,809 | $897,456 | $1,116,307 | | Intangible Assets, Net | $322,518 | $381,364 | $424,504 | | Total Assets | $2,212,221 | $2,415,727 | $2,771,327 | | Total Current Liabilities | $573,643 | $545,785 | $573,890 | | Revolving Credit Facility | $70,000 | $210,000 | $345,000 | | Notes Payable, Net | $846,463 | $845,872 | $845,280 | | Total Liabilities | $1,604,625 | $1,709,107 | $1,894,468 | | Stockholders' Equity | $607,596 | $706,620 | $876,859 | [Summary Condensed Consolidated Statements of Cash Flows](index=13&type=section&id=Summary%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section provides AMN Healthcare Services, Inc.'s unaudited summary condensed consolidated statements of cash flows for Q2 and H1 2025 and 2024 | Metric (Thousands USD) | Q2 2025 | Q2 2024 | Q1 2025 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | :--- | | Net Cash Provided by Operating Activities | $78,548 | $99,515 | $92,671 | $171,219 | $180,901 | | Net Cash Used in Investing Activities | ($20,591) | ($22,332) | ($26,046) | ($46,637) | ($43,731) | | Net Cash Used in Financing Activities | ($80,226) | ($80,108) | ($61,211) | ($141,437) | ($119,081) | | Cash, Cash Equivalents, and Restricted Cash, End of Period | $72,450 | $126,362 | $94,719 | $72,450 | $126,362 | [Supplemental Financial Data & Reconciliations](index=14&type=section&id=Supplemental%20Financial%20Data%20%26%20Reconciliations) [Non-GAAP Reconciliation Tables](index=14&type=section&id=Non-GAAP%20Reconciliation%20Tables) This section provides detailed reconciliation tables for non-GAAP financial measures like adjusted EBITDA, net income, and diluted EPS to their GAAP equivalents | Metric (Thousands USD) | Q2 2025 | Q2 2024 | Q1 2025 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | :--- | | Net Income (Loss) | ($116,202) | $16,237 | ($1,092) | ($117,294) | $33,565 | | Adjusted EBITDA | $58,289 | $94,087 | $64,200 | $122,489 | $191,753 | | Adjusted EBITDA Margin | 8.9% | 12.7% | 9.3% | 9.1% | 12.3% | | Adjusted Net Income | $11,561 | $37,332 | $17,327 | $28,888 | $74,560 | | Adjusted Diluted EPS | $0.30 | $0.98 | $0.45 | $0.75 | $1.95 | [Supplemental Segment Operating Data](index=15&type=section&id=Supplemental%20Segment%20Operating%20Data) This section provides supplemental operating data for each business segment, including average travelers, fill days, revenue per fill day, and leverage ratio | Business Segment | Q2 2025 | Q2 2024 | Q1 2025 | H1 2025 | H1 2024 | | :--- | :--- | :--- | :--- | :--- | :--- | | Nurse and Allied Solutions Revenue (Thousands USD) | $381,871 | $442,399 | $413,261 | $795,132 | $961,696 | | Physician and Leadership Solutions Revenue (Thousands USD) | $174,531 | $186,065 | $174,065 | $348,596 | $374,862 | | Technology and Workforce Solutions Revenue (Thousands USD) | $101,773 | $112,221 | $102,207 | $203,980 | $225,005 | | Average Travelers on Assignment | 8,700 | 10,302 | 8,981 | 8,841 | 10,913 | | Fill Days | 51,325 | 56,244 | 51,342 | 102,667 | 113,093 | | Revenue per Fill Day | $2,777 | $2,538 | $2,743 | $2,760 | $2,546 | | Metric | June 30, 2025 | December 31, 2024 | June 30, 2024 | | :--- | :--- | :--- | :--- | | Leverage Ratio | 3.3 | 3.0 | 2.6 | [Reconciliation of Guidance Operating Margin to Guidance Adjusted EBITDA Margin](index=16&type=section&id=Reconciliation%20of%20Guidance%20Operating%20Margin%20to%20Guidance%20Adjusted%20EBITDA%20Margin) This section reconciles Q3 2025 guidance for operating margin to adjusted EBITDA margin, detailing adjustments for depreciation, amortization, and other costs | Metric | September 30, 2025 (Low) | September 30, 2025 (High) | | :--- | :--- | :--- | | Operating Margin | 6.0% | 6.5% | | Depreciation and Amortization (Total) | 6.6% | 6.5% | | EBITDA Margin | 12.6% | 13.0% | | Smart Square Divestiture Gain | (6.5%) | (6.4%) | | Stock-Based Compensation Expense | 1.2% | 1.2% | | Integration and Other Costs | 0.4% | 0.4% | | Adjusted EBITDA Margin | 7.7% | 8.2% | [Notes to Non-GAAP Measures](index=17&type=section&id=Notes%20to%20Non-GAAP%20Measures) This section provides detailed notes on non-GAAP measures, explaining definitions, calculation methods, management's rationale for exclusions, and their limitations - Operating margin is defined as operating income (loss) divided by revenue[43](index=43&type=chunk) - Adjusted EBITDA excludes non-operating items such as depreciation, amortization, goodwill impairment, stock-based compensation, and M&A integration costs[43](index=43&type=chunk) - Adjusted Net Income and Adjusted Diluted EPS exclude intangible asset amortization, M&A integration costs, goodwill impairment, and tax impacts[43](index=43&type=chunk) - These non-GAAP metrics aim to provide a more consistent basis for period-over-period comparisons but involve management judgment and should not replace GAAP measures[44](index=44&type=chunk)

Financial Performance - AMN Healthcare reported quarterly revenue of $658 million, an 11% decrease year-over-year and a 5% decrease sequentially [5][8] - The company experienced a net loss of $116.2 million, translating to a diluted loss per share of ($3.02) [5][13] - Adjusted diluted EPS was $0.30, down 69% from the same quarter last year [5][13] Segment Performance - Revenue from the Nurse and Allied Solutions segment was $382 million, a 14% decline year-over-year and an 8% decline from the previous quarter [6][38] - The Physician and Leadership Solutions segment reported revenue of $175 million, down 6% year-over-year and flat sequentially [7][38] - Technology and Workforce Solutions segment revenue was $102 million, a decrease of 9% year-over-year and flat sequentially [10][38] Operational Highlights - The company achieved a consolidated gross margin of 29.8%, which is 120 basis points lower year-over-year but improved by 110 basis points sequentially [11][38] - SG&A expenses were $155 million, representing 23.5% of revenue, an increase from 20.1% in the same quarter last year [12][38] - Cash flow from operations was strong at $79 million, allowing the company to reduce debt by $80 million, resulting in a net leverage ratio of 3.3:1 [8][14] Future Outlook - For Q3 2025, consolidated revenue is expected to be 9-11% lower than the prior year, with specific segment declines projected [17][18] - The company anticipates a gross margin between 28.7% and 29.2% for the upcoming quarter [17] - Labor disruption revenue assumed in guidance is $5 million [18] Strategic Developments - The sale of Smart Square for $75 million is part of the company's strategy to enhance its partnership with symplr [15][16] - AMN Passport, the company's app for healthcare professionals, surpassed 300,000 users, indicating growth in its technology-enabled services [8]

Core Insights - The average starting salary for physicians is $403,000, with orthopedic surgeons earning the highest at $576,000 and pediatricians the lowest at $258,000 [1][2][3] Salary Trends - Specialists, particularly orthopedic surgeons, gastroenterologists ($552,000), urologists ($521,000), radiologists ($500,000), and hematologists/oncologists ($490,000), command the highest starting salaries [2][3] - The average starting salary for otolaryngologists increased by 36% from $358,000 to $487,000, while cardiologists saw a 19% increase from $396,000 to $470,000, and hematologists/oncologists increased by 10% from $444,000 to $490,000 [4] Demand for Healthcare Professionals - There is a strong demand for specialists driven by the growing senior citizen population, leading to high starting salary offers [3] - The five specialties with the most demand are hematologists/oncologists, gastroenterologists, endocrinologists, and radiologists, although job prospects are abundant across all medical specialties [5][6] Nurse Practitioners (NPs) Salary Insights - The average starting salary for NPs is $180,000, reflecting a 9.6% increase from $164,000 in 2024 [5] Additional Compensation - Physicians are offered an average signing bonus of $38,315 (up 23% from $31,103), a relocation allowance of $12,619 (up 12% from $11,284), and a continuing medical education allowance of $4,073 (up 3% from $3,969) [6][7] - The combined average of signing bonuses, relocation, and CME allowances totals $58,854, in addition to the average starting salary of $403,000 [7] Report Overview - The data is based on a representative sample of 1,420 search engagements conducted by AMN Healthcare from April 1, 2024, to March 31, 2025 [8]

Core Viewpoint - AMN Healthcare Services (AMN) is expected to report a year-over-year decline in earnings and revenues for the quarter ended June 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is anticipated to show earnings of $0.17 per share, reflecting a significant year-over-year decrease of 82.7% [3]. - Revenues are projected to be $652.49 million, which is an 11.9% decline from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 8.43% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for AMN is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.58% [12]. Earnings Surprise Prediction - A positive Earnings ESP reading suggests a potential earnings beat, but the current Zacks Rank of 4 indicates a lower likelihood of this outcome [10][12]. - Historical performance shows that AMN has beaten consensus EPS estimates in the last four quarters, with a notable surprise of +136.84% in the most recent quarter [13][14]. Industry Comparison - Charles River Laboratories (CRL), another player in the medical services industry, is expected to report earnings of $2.5 per share, down 10.7% year-over-year, with revenues of $982.87 million, a 4.2% decline [18][19]. - CRL has a positive Earnings ESP of +0.11% and a Zacks Rank of 3, indicating a higher likelihood of beating consensus EPS estimates [20].

Group 1 - AMN Healthcare Services, Inc. has scheduled a conference call for August 7, 2025, to discuss its Q2 2025 financial results and Q3 2025 outlook [1] - The earnings news release is expected to be issued after market close on the same day at approximately 4:15 p.m. Eastern Time [1] - A live webcast of the call will be accessible through a provided link and on AMN Healthcare's investor relations website [2] Group 2 - Following the call, a replay of the webcast will be available on the Company's investor relations website [3] - AMN Healthcare is recognized as a leader in total talent solutions for healthcare, addressing workforce challenges to improve clinical outcomes [4] - In 2024, AMN Healthcare professionals reached nearly 15 million patients across over 2,100 healthcare systems, including 87% of the top healthcare systems nationwide [4] Group 3 - The Company's common stock is listed under the symbol "AMN" on the New York Stock Exchange [5] - AMN Healthcare provides various channels for distributing information, including email alerts and RSS feeds [5] - Contact information for investor relations is available, including a dedicated Vice President for Investor Relations and Strategy [6]

Core Insights - AMN Healthcare Services, Inc. announced the sale of its Smart Square scheduling software to symplr for $75 million, establishing a commercial partnership to enhance operational technology and workforce solutions [1][10] - The partnership is expected to strengthen AMN's Scheduling and Staff Planning business, boosting its position in the healthcare workforce management niche [2] Company Performance - Following the announcement, AMN's shares gained nearly 0.5%, reflecting positive market sentiment [3] - AMN Healthcare has a market capitalization of $843.9 million and an earnings yield of 4.8%, outperforming the industry average of 4.2% [4] Strategic Rationale - AMN Healthcare aims to meet the increasing demand for integrated workforce management solutions by combining its capabilities with symplr's software, which is expected to streamline various administrative processes for healthcare organizations [5][6] - The partnership is anticipated to enhance AMN's WorkWise technology suite, providing clients with a comprehensive solution for workforce management [6] Industry Outlook - The global workforce management market was valued at $8.07 billion in 2022 and is projected to reach $19.35 billion by 2030, growing at a CAGR of 11.7%, driven by workforce optimization and technological advancements [8] - The recent announcement is expected to significantly boost AMN Healthcare's business in light of the market potential [8] Recent Developments - In May, AMN reported a 4.9% year-over-year increase in revenues from its Technology and Workforce Solutions segment's Language services [9]

Company Overview - AMN Healthcare is a leader and innovator in total talent solutions for healthcare, uniquely positioned to serve growing health systems and diverse care settings[5] - The company has over 12,000 total employees[8] - AMN Healthcare has a strong ESG/CSR track record[8] Financial Performance - In 2019, AMN Healthcare's revenue was $2.222 billion, with a gross profit of $743 million and a gross margin of 33.5%[8] - Adjusted EBITDA for 2019 was $277 million, representing an adjusted EBITDA margin of 12.5%[8] - Free cash flow in 2019 was $190 million, with a free cash flow conversion rate of 68%[8] - As of Q3 2020, Nurse and Allied Solutions accounted for 69% of revenue, Physician and Leadership Solutions 20%, and Technology and Workforce Solutions 11%[8, 11] - Managed Services Programs (MSPs) account for 56% of revenue from these segments[12] Market Position and Strategy - AMN Healthcare manages over $3.4 billion in spend under management[19] - The company is well-positioned to capture long-term U.S secular trends, including the aging population and healthcare professionals, job openings/turnover, and healthcare spend[37] - The total addressable market is approximately $22 billion, including $17 billion for the U.S Healthcare Staffing Market and $5 billion for other addressable markets[42, 43] - The company's strategic approach to M&A focuses on accretive profit margins and revenue growth, with a ROIC greater than the cost of capital[104]

Core Insights - The article discusses the potential for AMN Healthcare Services, Inc. to experience accelerated free cash flow growth due to shifts in US age demographics and the implementation of its WorkWise and ShiftWise solutions [1]. Company Overview - AMN Healthcare Services, Inc. is positioned to benefit from demographic changes in the US, which may lead to increased demand for its services [1]. Investment Strategy - The author emphasizes a focus on small and medium-cap companies, particularly in mature industries such as mining, oil and gas, and real estate, indicating a preference for deep value investments and dividend investing [1]. Financial Expectations - The author targets an internal rate of return of approximately 5%-7% for investments, reflecting a conservative investment approach [1].

Core Insights - AMN Healthcare has sold its Smart Square® scheduling software to symplr and entered into a commercial partnership to enhance healthcare workforce solutions [1][2][3] - The partnership aims to integrate AMN's workforce planning and analytics capabilities with symplr's operational technology, addressing the complexities of healthcare workforce management [2][3][4] - The total purchase price for the software was $75 million, with $65 million paid at closing and a $10 million note due at the end of 2026 [5] Company Overview - AMN Healthcare is a leader in total healthcare talent solutions, providing a comprehensive network of healthcare professionals and customizable workforce technologies [6] - In 2024, AMN's healthcare professionals reached nearly 15 million patients across more than 2,100 healthcare systems, including 87% of the top healthcare systems in the U.S. [6] - symplr is recognized as a leader in enterprise healthcare operations software, trusted by 9 out of 10 U.S. hospitals and over 400 health plans [7]

Core Insights - symplr has acquired Smart Square scheduling software from AMN Healthcare, enhancing its healthcare workforce and operations management capabilities [1][2] - The acquisition strengthens the symplr Operations Platform by integrating AI-driven scheduling and workforce management solutions [2][3] - symplr aims to empower healthcare organizations with actionable data and technology to improve efficiencies and patient outcomes [3][4] Company Overview - symplr is a leader in enterprise healthcare operations software, trusted by 9 out of 10 U.S. hospitals and over 400 U.S. health plans [6] - AMN Healthcare is recognized for its total talent solutions in healthcare, reaching nearly 15 million patients across more than 2,100 healthcare systems in 2024 [7] - Clearlake Capital Group and Charlesbank Capital Partners are the backing investment firms for symplr, with Clearlake managing over $90 billion in assets [9][10] Strategic Implications - The acquisition of Smart Square is expected to enhance symplr's offerings in workforce planning, analytics, and AI, addressing the complexities of healthcare staffing [5] - The partnership between symplr and AMN Healthcare aims to combine operational technology expertise with workforce solutions, benefiting customers [4][5] - The integration of Smart Square's AI capabilities is positioned to help healthcare organizations anticipate staffing needs and streamline operations [3][4]